TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) Net Income (Loss) Attributable to Parent USD 2010 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Teva Pharmaceutical Industries Ltd quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2010 to 2024.
  • Teva Pharmaceutical Industries Ltd Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$139 M, a 36.8% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$478 M, a 72.1% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd annual Net Income (Loss) Attributable to Parent for 2023 was -$559 M, a 77.1% increase from 2022.
  • Teva Pharmaceutical Industries Ltd annual Net Income (Loss) Attributable to Parent for 2022 was -$2.45 B, a 687% decline from 2021.
  • Teva Pharmaceutical Industries Ltd annual Net Income (Loss) Attributable to Parent for 2021 was $417 M.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$478 M -$139 M +$81 M +36.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$559 M $462 M +$1.76 B Oct 1, 2023 Dec 31, 2023 10-K 2024-02-12
Q3 2023 -$2.32 B $70 M +$9 M +14.8% Jul 1, 2023 Sep 30, 2023 10-K 2024-02-12
Q2 2023 -$2.33 B -$871 M -$620 M -247% Apr 1, 2023 Jun 30, 2023 10-K 2024-02-12
Q1 2023 -$1.71 B -$220 M +$735 M +77% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$2.45 B -$1.3 B -$1.14 B -718% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-12
Q3 2022 -$1.3 B $61 M -$231 M -79.1% Jul 1, 2022 Sep 30, 2022 10-K 2024-02-12
Q2 2022 -$1.07 B -$251 M -$458 M -221% Apr 1, 2022 Jun 30, 2022 10-K 2024-02-12
Q1 2022 -$615 M -$955 M -$1.03 B -1340% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $417 M -$159 M -$309 M -206% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-12
Q3 2021 $726 M $292 M +$4.64 B Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$3.92 B $207 M +$67 M +47.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-27
Q1 2021 -$3.98 B $77 M +$8 M +11.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 -$3.99 B $150 M +$40 M +36.4% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-10
Q3 2020 -$4.03 B -$4.35 B -$4.04 B -1285% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-27
Q2 2020 $5 M $140 M +$829 M Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-28
Q1 2020 -$824 M $69 M +$174 M Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-28
Q4 2019 -$998 M $110 M +$3 B Oct 1, 2019 Dec 31, 2019 10-K 2021-02-10
Q3 2019 -$3.99 B -$314 M -$106 M -51% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-10
Q2 2019 -$3.89 B -$689 M -$513 M -291% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-10
Q1 2019 -$3.38 B -$105 M -$1.23 B -109% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-10
Q4 2018 -$2.15 B -$2.89 B +$8.65 B +75% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-21
Q3 2018 -$10.8 B -$208 M -$803 M -135% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-21
Q2 2018 -$10 B -$176 M +$5.79 B +97.1% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-21
Q1 2018 -$15.8 B $1.12 B +$475 M +73.6% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-21
Q4 2017 -$16.3 B -$11.5 B -$10.6 B -1086% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-19
Q3 2017 -$5.7 B $595 M +$183 M +44.4% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-19
Q2 2017 -$5.89 B -$5.97 B -$6.22 B -2450% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-19
Q1 2017 $338 M $645 M +$9 M +1.42% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-19
Q4 2016 $329 M -$973 M -$1.47 B -295% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-12
Q3 2016 $1.8 B $412 M +$309 M +300% Jul 1, 2016 Sep 30, 2016 6-K 2017-11-02
Q2 2016 $1.49 B $254 M -$285 M -52.9% Apr 1, 2016 Jun 30, 2016 6-K 2017-08-03
Q1 2016 $1.78 B $636 M +$190 M +42.6% Jan 1, 2016 Mar 31, 2016 6-K 2017-05-11
Q4 2015 $1.59 B $500 M -$187 M -27.2% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-12
Q3 2015 $1.78 B $103 M -$773 M -88.2% Jul 1, 2015 Sep 30, 2015 6-K 2016-11-15
Q2 2015 $2.55 B $539 M -$209 M -27.9% Apr 1, 2015 Jun 30, 2015 6-K 2016-08-04
Q1 2015 $2.76 B $446 M -$298 M -40.1% Jan 1, 2015 Mar 31, 2015 6-K 2016-05-09
Q4 2014 $3.06 B $687 M +$307 M +80.8% Oct 1, 2014 Dec 31, 2014 20-F 2017-02-15
Q3 2014 $2.75 B $876 M +$165 M +23.2% Jul 1, 2014 Sep 30, 2014 6-K 2015-10-29
Q2 2014 $2.58 B $748 M +$1.2 B Apr 1, 2014 Jun 30, 2014 6-K 2015-07-30
Q1 2014 $1.38 B $744 M +$114 M +18.1% Jan 1, 2014 Mar 31, 2014 6-K 2015-04-30
Q4 2013 $1.27 B $380 M +$60 M +18.8% Oct 1, 2013 Dec 31, 2013 20-F 2016-02-11
Q3 2013 $1.21 B $711 M +$790 M Jul 1, 2013 Sep 30, 2013 6-K 2014-10-30
Q2 2013 $419 M -$452 M -$1.32 B -152% Apr 1, 2013 Jun 30, 2013 6-K 2014-07-31
Q1 2013 $1.73 B $630 M -$229 M -26.7% Jan 1, 2013 Mar 31, 2013 6-K 2014-05-02
Q4 2012 $1.96 B $320 M -$186 M -36.8% Oct 1, 2012 Dec 31, 2012 20-F 2015-02-09
Q3 2012 $2.15 B -$79 M -$995 M -109% Jul 1, 2012 Sep 30, 2012 6-K 2013-10-31
Q2 2012 $3.14 B $863 M +$287 M +49.8% Apr 1, 2012 Jun 30, 2012 6-K 2013-08-01
Q1 2012 $2.86 B $859 M +$98 M +12.9% Jan 1, 2012 Mar 31, 2012 6-K 2013-05-02
Q4 2011 $2.76 B $506 M -$265 M -34.4% Oct 1, 2011 Dec 31, 2011 20-F 2014-02-10
Q3 2011 $3.02 B $916 M -$134 M -12.8% Jul 1, 2011 Sep 30, 2011 6-K 2012-11-01
Q2 2011 $3.16 B $576 M -$221 M -27.7% Apr 1, 2011 Jun 30, 2011 6-K 2012-08-02
Q1 2011 $3.38 B $761 M +$48 M +6.73% Jan 1, 2011 Mar 31, 2011 6-K 2012-05-09
Q4 2010 $3.33 B $771 M Oct 1, 2010 Dec 31, 2010 20-F 2013-02-12
Q3 2010 $1.05 B Jul 1, 2010 Sep 30, 2010 6-K 2011-11-02
Q2 2010 $797 M Apr 1, 2010 Jun 30, 2010 6-K 2011-07-28
Q1 2010 $713 M Jan 1, 2010 Mar 31, 2010 6-K 2011-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.